Dasatinib synergizes with doxorubicin to block growth, migration, and invasion of breast cancer cells

C. S. Pichot, S. M. Hartig, L. Xia, C. Arvanitis, D. Monisvais, F. Y. Lee, J. A. Frost, S. J. Corey

Research output: Contribution to journalArticlepeer-review

116 Scopus citations

Abstract

Background:Src family kinases control multiple cancer cell properties including cell cycle progression, survival, and metastasis. Recent studies suggest that the Src inhibitor dasatinib blocks these critical cancer cell functions.Methods:Because the molecular mechanism of action of dasatinib in breast cancers has not been investigated, we evaluated the effects of dasatinib as a single agent and in combination with the commonly used chemotherapeutic doxorubicin, on the proliferation, viability, and invasive capacity of breast cancer cells lines earlier categorised as dasatinib-sensitive (MDA-MB-231) and moderately resistant (MCF7 and T47D). We also tested the effects of these drugs on the actin cytoskeleton and associated signalling pathways.Results:The cell lines tested varied widely in sensitivity to growth inhibition (IC 50 0.16-12.3 M), despite comparable Src kinase inhibition by dasatinib (IC 50 17-37 nM). In the most sensitive cell line, MDA-MB-231, dasatinib treatment induced significant G 1 accumulation with little apoptosis, disrupted cellular morphology, blocked migration, inhibited invasion through Matrigel (P0.01), and blocked the formation of invadopodia (P0.001). Importantly, combination treatment with doxorubicin resulted in synergistic growth inhibition in all cell lines and blocked the migration and invasion of the highly metastatic, triple-negative MDA-MB-231 cell line.Conclusion:The observed synergy between dasatinib and doxorubicin warrants the re-evaluation of dasatinib as an effective agent in multi-drug regimens for the treatment of invasive breast cancers.

Original languageEnglish (US)
Pages (from-to)38-47
Number of pages10
JournalBritish Journal of Cancer
Volume101
Issue number1
DOIs
StatePublished - Jul 7 2009

Keywords

  • Breast cancer
  • Dasatinib
  • Invadopodia
  • Invasion
  • Src

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Dasatinib synergizes with doxorubicin to block growth, migration, and invasion of breast cancer cells'. Together they form a unique fingerprint.

Cite this